ASCRS 2024: 10-year results from a real-world study shed new light on glaucoma

News
Video

At ASCRS in Boston, Paul Harasymowycz, MD shared a decade's worth of data on MIGS procedures for primary open-angle glaucoma

At this year's ASCRS meeting in Boston, Massachusetts, we caught up with Paul Harasymowycz, MD, who detailed his presentation "Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma." Here, he shares the highlights from a decade's worth of data.

Editor's note: The below transcript has been lightly edited for clarity.

Hello, I'm Dr Paul Harasymowycz, from University of Montreal and McGill University. Today we have the pleasure of presenting our 10-year results of using two [first-generation trabecular micro bypass] iStents with cataract surgery. So that's a decade of results using MIGS surgery. I think that's a very important contribution to our knowledge.

This was a real world study. In the end, we had 56 patients that we followed over time. The most important is that they had OCT stability up until 10 years. The average pressure before was higher than 18. And even after 10 years, a decade, their pressure was almost at 14. That's very important. Another finding in our study was that 75% of our patients, their pressure was below 15. And we know, usually, the lower we keep the pressure, the less likelihood is that their glaucoma will progress. And so I think that's great for our patients. In the end, it's all about the patients. And the study does show that using angle surgery may be beneficial to your patients as well.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.